Protalix BioTherapeutics Inc has announced a new strategy for company growth.
Protalix is working on opening efficacy clinical trials for AIR DNase for CF in a non-IND setting within the year, and finalizing and releasing results sometime in early 2016. Afterward, the company plans to close a partnership agreement with an appropriate company for further research and development.
